NIH R01 · 2025
Corticosteroids to Reduce Inflammation in Severe Pancreatitis (CRISP)
ABSTRACT There are currently limited medicinal interventions demonstrated to improve outcomes in patients with acute severe non-autoimmune pancreatitis, a highly morbid and potentially fatal condition which is estimated to afflict up to 275,000 patients annually in the US.[1] Early-stage mild pancreatitis often self-resolves; however 15-20% of cases [2] progress to a severe form characterized by a potentially lethal systemic inflammatory response syndrome with injury to multiple organs and (frequently) respiratory failure. Further clinical deterioration can lead to necrotizing pancreatitis, which is clinically similar to sepsis and has a reported mortality of up to 30%. [3–6] Although…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.